<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357106</url>
  </required_header>
  <id_info>
    <org_study_id>CHMI-030420-01</org_study_id>
    <nct_id>NCT04357106</nct_id>
  </id_info>
  <brief_title>COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma</brief_title>
  <acronym>COPLA</acronym>
  <official_title>COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Hematología y Medicina Interna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorios Clínicos de Puebla (Laboratorios Ruiz)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro de Hematología y Medicina Interna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 disease has become a very serious global health problem. Treatments for severe forms
      are urgently needed to lower mortality. Any procedure that improves these forms should be
      considered, especially those devoid of serious side effects.There is not enough published
      information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe
      forms of COVID-19. The use of ACP can be combined with other treatments and has very few
      adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce
      virus-neutralizing antibodies: within that time they can develop serious complications and
      die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk
      while the patient produces the antibodies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lung injury</measure>
    <time_frame>7 days</time_frame>
    <description>PaO2/FiO2 relation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>15-30 days</time_frame>
    <description>Patients survival after therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions to plasma</measure>
    <time_frame>7 days</time_frame>
    <description>Determine the incidence of side effects from plasma administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Convalescent Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 ml of convalescent plasma, single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Convalescent plasma obtained by aphaeresis from recovered patients.</description>
    <arm_group_label>Convalescent Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SARS-CoV2 infection who have had a serious evolution and are in an ICU

          -  With or without ventilatory assistance

          -  Treated or not with hydroxychloroquine 200 mg. every 12 hours

          -  Indistinct sex

          -  Older than 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients treated with the following medications: azithromycin, ritonavir / lopinavir,
             remdesivir, interferons, ruxolinitib, tocilizumab.

          -  Patients with severe kidney failure who require replacement therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Carlos Olivares-Gazca, MD, MPH</last_name>
    <phone>2222438100</phone>
    <email>jolivares@hsctmexico.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José Manuel Priesca-Marin, MD</last_name>
    <phone>2222438100</phone>
    <email>mpriesca@hsctmexico.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Hematología y Medicina Interna</name>
      <address>
        <city>Puebla</city>
        <zip>72530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Carlos Olivares-Gazca, MD,MPH</last_name>
      <phone>2222438100</phone>
      <email>jolivares@hsctmexico.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo J Ruiz-Arguelles, MD, FRCP, MACP, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Hematología y Medicina Interna</investigator_affiliation>
    <investigator_full_name>Guillermo J. RUIZ-ARGÜELLES</investigator_full_name>
    <investigator_title>Dr. Guillermo J. Ruiz-Argüelles</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

